Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy
{{output}}
Background: Selinexor, a first-in-class, oral exportin-1 inhibitor, showed activity in penta-refractory multiple myeloma (MM) in early trial exploration; however, the side-effect profile of twice-weekly dosing led to hesitant inc... ...
